<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026973</url>
  </required_header>
  <id_info>
    <org_study_id>13-007623</org_study_id>
    <nct_id>NCT02026973</nct_id>
  </id_info>
  <brief_title>Impact of Endogenous E2 on SSI and GH Rebound</brief_title>
  <official_title>Impact of Endogenous Estrogen on Somatostatin Inhibition and Growth Hormone Rebound in Older Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by
      potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin
      inhibition of GH release.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic concentrations of testosterone (Te), estradiol (E2), GH, IGF-I and IGFBP-3 decline
      in healthy aging individuals (1-3). Sex-steroid deprivation accentuates GH and IGF-I
      depletion, since Te and E2 stimulate GH and IGF-I production in older adults, hypogonadal
      patients of all ages, and patients undergoing gender reassignment (1,2,4). Tamoxifen blocks
      the effect of Te, suggesting involvement of E2 in GH's stimulation in men (5). E2 also
      stimulates GH secretion in women, putatively via the nuclear estrogen receptor (ER-alpha)
      (1,2,6,7). Because Te, E2 and GH fall with menopause, and Te is converted to E2 by
      aromatization in the body (8-10), we postulate that diminished Te concentrations, Teâ†’E2
      concentrations and low E2 mediate low GH output in older women. What remains unknown is
      whether the low E2 levels in postmenopausal women retain GH-stimulating effects. To test this
      notion would require blocking: (i) aromatase-enzyme activity, which mediates E2 synthesis
      from Te, and/or (ii) estrogen receptor-alpha, which transduces most of E2's stimulation of
      the GH axis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The summed mass of GH over 10 hours.</measure>
    <time_frame>14-18 days: From date of randomization to overnight visit</time_frame>
    <description>Subjects will be given placebo/fulvestrant and placebo/anastrozole on Day 1 to take for 14-18 days. For one night between Days 14-18, from date of randomization, subjects will undergo a 15-h overnight (2200-1300h) fasting, 10-min blood sampling. The primary analytical outcome is the summed mass of GH secreted in pulses over the first 10h of overnight blood samples. Pulsatile GH is relevant, since sex-steroid hormones and regulatory peptides uniquely control GH secretory-burst mass.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The summed mass of GH over a 2h Somatostatin infusion and 3h rebound window</measure>
    <time_frame>14-18 days: From date of randomization to overnight visit</time_frame>
    <description>Subjects will be given placebo/fulvestrant and placebo/anastrozole on Day 1 to take for 14-18 days. For one night between Days 14-18, from date of randomization, subjects will undergo a 15-h overnight (2200-1300h) fasting, 10-min blood sampling. The secondary outcome is summed GH secretory-burst-mass values during the overnight visit, specifically: a 2-h somatostatin infusion and subsequent 3-h rebound window.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Normal Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>IM Placebo/Oral Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM Placebo/PO Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM Fulvestrant/PO Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM Fulvestrant/IM Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>IM Fulvestrant/PO Placebo</arm_group_label>
    <arm_group_label>IM Fulvestrant/IM Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>IM Placebo/PO Anastrozole</arm_group_label>
    <arm_group_label>IM Fulvestrant/IM Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>IM Placebo/Oral Placebo</arm_group_label>
    <arm_group_label>IM Placebo/PO Anastrozole</arm_group_label>
    <arm_group_label>IM Fulvestrant/PO Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <arm_group_label>IM Placebo/Oral Placebo</arm_group_label>
    <arm_group_label>IM Placebo/PO Anastrozole</arm_group_label>
    <arm_group_label>IM Fulvestrant/PO Placebo</arm_group_label>
    <arm_group_label>IM Fulvestrant/IM Anastrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. 60 healthy post-menopausal women (ages 55 to 80 y);

          2. BMI 18-30 kg/m2

          3. Community dwelling; and voluntarily consenting

        Exclusion:

          1. Recent use of psychotropic or neuroactive drugs (within five biological half-lives);

          2. Obesity (outside weight range above);

          3. Laboratory test results not deemed physician acceptable, cholesterol &gt;250,
             triglycerides &gt; 300, BUN &gt;30 or creatinine &gt; 1.5 mg/dL, liver function tests exceeding
             twice upper limit of normal, electrolyte abnormality, anemia;

          4. Drug or alcohol abuse, psychosis, depression, mania or severe anxiety;

          5. Systemic inflammatory disease;

          6. Endocrinopathy, other than primary thyroidal failure receiving replacement;

          7. Nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days
             of CRU admission);

          8. Acute weight change (loss or gain of &gt; 2 kg in 6 weeks);

          9. Systemic illness

         10. Unwillingness to provide written informed consent.

         11. Allergy to anastrozole or fulvestrant (treatment drugs).

         12. History or suspicion of breast cancer.

         13. History of carcinoma (excluding localized basal cell carcinoma removed or surgically
             treated with no recurrence).

         14. History of thrombotic arterial disease (stroke, TIA, MI, angina) or deep-vein
             thrombophlebitis.

         15. History of CHF, cardiac arrhythmias, congenital QT prolongation, and medications used
             to treat cardiac arrhythmias.

         16. Pre-menopausal status as determined by screening hormone measurements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Veldhuis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Johannes D. Veldhuis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

